Literature DB >> 18025575

Enhanced expression and primary purification of soluble HBD3 fusion protein in Escherichia coli.

Lei Huang1, Zhinan Xu, Zhixia Zhong, Li Peng, Haiqin Chen, Peilin Cen.   

Abstract

Human beta-defensin-3(HBD3) is a low molecular weight cationic peptide with a broad antimicrobial spectrum. A recombinant Escherichia coli (pET32-smHBD3) was constructed to produce HBD3 fusion protein (TrxA-HBD3) before, but the productivity is relatively low. In the present work, the effects of different expression conditions were systematically investigated to improve the expression level of the fusion protein. With regard to the volumetric productivity, the optimal conditions were determined as follows: cultivation at 34 degrees C in MBL medium, induction at middle stage of the exponential growth phase with 0.4 mM isopropylthio-D-galactoside, and postinduction expression for 8 h. Under these conditions, the volumetric productivity of the fusion protein reached 2.55 g/L, i.e., 0.55 g mature HBD3/L, which was about 2.6 times of that obtained under the unoptimized conditions. And the target protein still maintained high solubility (> or =97.9%) and accounted for 66% of the total soluble protein. A cationic exchange purification step was employed to obtain high-purity target protein (90%) with a recovery ratio of 78%. This soluble expression level of HBD3 fusion protein was the highest among all the reported literature and facilitated the development of high efficient purification of HBD3.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18025575     DOI: 10.1007/s12010-007-0009-4

Source DB:  PubMed          Journal:  Appl Biochem Biotechnol        ISSN: 0273-2289            Impact factor:   2.926


  5 in total

1.  An efficient method for bacterial production and activity assessment of recombinant human insulin like growth factor 1.

Authors:  Fatemeh Aboutalebi; Liana Lachinani; Yahya Khazaei; Mahboobeh Forouzanfar; Mohammad Hossein Nasr-Esfahani; Kamran Ghaedi; Kianoush Dormiani
Journal:  Mol Biol Rep       Date:  2018-09-10       Impact factor: 2.316

2.  Human neutrophil peptide-1 (HNP-1): a new anti-leishmanial drug candidate.

Authors:  Sara Dabirian; Yasaman Taslimi; Farnaz Zahedifard; Elham Gholami; Fatemeh Doustdari; Mahdieh Motamedirad; Shohreh Khatami; Kayhan Azadmanesh; Susanne Nylen; Sima Rafati
Journal:  PLoS Negl Trop Dis       Date:  2013-10-17

3.  Enhanced Production of Insulin-like Growth Factor I Protein in Escherichia coli by Optimization of Five Key Factors.

Authors:  Javad Ranjbari; Valiollah Babaeipour; Hossein Vahidi; Hamidreza Moghimi; Mohammad Reza Mofid; Mohammad Mehdi Namvaran; Sevda Jafari
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

4.  The effect of cell disruption techniques and chaotropic agents on the downstream purification process of mecasermin produced as inclusion body in E. coli.

Authors:  Leila Haddad; Valiollah Babaeipour; Mohammad Reza Mofid
Journal:  Res Pharm Sci       Date:  2015 Nov-Dec

5.  Expression of recombinant HBD3 protein that reduces Mycobacterial infection capacity.

Authors:  Feng Su; Xin Chen; Xin Liu; Guanghui Liu; Yong Zhang
Journal:  AMB Express       Date:  2018-03-20       Impact factor: 3.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.